Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

597.50INR
10:15am EDT
Price Change (% chg)

Rs1.30 (+0.22%)
Prev Close
Rs596.20
Open
Rs600.70
Day's High
Rs601.50
Day's Low
Rs596.00
Volume
60,434
Avg. Vol
1,077,804
52-wk High
Rs667.60
52-wk Low
Rs305.20

RANB.NS

Chart for RANB.NS

About

Ranbaxy Laboratories Limited is an integrated international pharmaceuticals company. The Company is engaged in the marketing, production and distribution of pharmaceutical products. The Company’s business activity falls within a single primary business segment viz. Pharmaceutical. The Company has ground operations in over 40... (more)

Overall

Beta: 0.66
Market Cap (Mil.): Rs253,130.41
Shares Outstanding (Mil.): 424.57
Dividend: --
Yield (%): --

Financials

  RANB.NS Industry Sector
P/E (TTM): -- 32.88 33.65
EPS (TTM): -20.63 -- --
ROI: -- 18.21 17.48
ROE: -- 18.89 18.31
Search Stocks

INDIA PRESS-Ranbaxy staff get pay-cut shield in Sun buyout - Business Standard

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Derek Francis in Bangalore)

19 Oct 2014

India's Ranbaxy to pay $40 million to settle Texas Medicaid pricing litigation

MUMBAI - Indian generic drugmaker Ranbaxy Laboratories Ltd said it has agreed to pay $39.75 million to settle litigation concerning its participation in Texas Medicaid, the U.S. federal-state healthcare program for people with low incomes.

16 Oct 2014

UPDATE 1-India's Ranbaxy to pay $40 mln to settle Texas Medicaid pricing litigation

* Ranbaxy shares up 0.6 percent in Mumbai (Adds settlement details, analyst views, updates share price)

16 Oct 2014

India's Ranbaxy to pay $40 mln to settle Texas Medicaid pricing litigation

MUMBAI, Oct 16 - Indian generic drugmaker Ranbaxy Laboratories Ltd said it had agreed to pay $39.75 million to settle litigations concerning its participation in Texas Medicaid, the US federal-state healthcare program for the poor.

16 Oct 2014

INDIA PRESS-Ranbaxy's US subsidiary sees 5 top-level exits - Economic Times

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Derek Francis in Bangalore)

13 Oct 2014

India caps prices of 36 more drugs to improve access: government official

NEW DELHI/MUMBAI - India has capped the prices of 36 drugs, including those used to treat infections and diabetes, in its latest move to make essential medicines more affordable, a senior official of the country's drug pricing authority told Reuters on Friday.

19 Sep 2014

UPDATE 2-India caps prices of 36 more drugs to improve access -govt official

* Local firms Cipla, Ranbaxy, Cadila among companies affected

19 Sep 2014

India's Ranbaxy says U.S. authorities seek information on pricing data

MUMBAI - Indian generic drugmaker Ranbaxy Laboratories Ltd said on Wednesday that federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid program.

17 Sep 2014

India's Ranbaxy says US authorities seek information on pricing data

MUMBAI, Sept 17 - Indian generic drugmaker Ranbaxy Laboratories Ltd said on Wednesday that federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid program.

17 Sep 2014

Epirus, Ranbaxy win India approval for arthritis drug copy

- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

15 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00
Provider: Motilal Oswal Securities Ltd.
$81.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks